Atalanta Technologies
Atalanta Technologies Inc.
Atalanta Therapeutics is a biotechnology company focused on developing RNA interference (RNAi) therapies for severe neurological diseases. The company utilizes a proprietary technology platform, co-developed by Nobel laureate Craig Mello, designed to effectively deliver gene-silencing therapies throughout the brain and spinal cord, an area that has historically been a significant challenge for RNAi treatments. Supported by major pharmaceutical partnerships and substantial funding, Atalanta is advancing a pipeline of investigational therapies for conditions like Huntington's disease and severe epilepsy.
Products & Team
Proprietary RNAi Platform (di-siRNA Technology)
Atalanta's core offering is its therapeutic development platform based on a novel oligonucleotide structure known as divalent small interfering RNA (di-siRNA). This technology is engineered to overcome the primary challenge of delivering RNAi therapeutics across the blood-brain barrier, enabling broad distribution and targeted gene silencing throughout the brain and spinal cord.
The platform solves the critical delivery problem that has limited the application of RNAi therapies for neurological disorders, offering a potential new treatment modality for diseases caused by specific gain-of-function gene variants.
Patients with these conditions often lack effective disease-modifying treatments. Existing therapies typically manage symptoms rather than addressing the root genetic cause, which is the problem Atalanta's gene-silencing approach aims to solve.